RU2745912C2 - Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции - Google Patents
Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции Download PDFInfo
- Publication number
- RU2745912C2 RU2745912C2 RU2018140131A RU2018140131A RU2745912C2 RU 2745912 C2 RU2745912 C2 RU 2745912C2 RU 2018140131 A RU2018140131 A RU 2018140131A RU 2018140131 A RU2018140131 A RU 2018140131A RU 2745912 C2 RU2745912 C2 RU 2745912C2
- Authority
- RU
- Russia
- Prior art keywords
- improving
- pharmaceutically acceptable
- acceptable salt
- function
- disorder
- Prior art date
Links
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title abstract 2
- 229960000669 acetylleucine Drugs 0.000 title abstract 2
- 230000007659 motor function Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 230000003920 cognitive function Effects 0.000 title 1
- 206010017577 Gait disturbance Diseases 0.000 abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005021 gait Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606834.8 | 2016-04-19 | ||
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021107001A Division RU2837641C2 (ru) | 2016-04-19 | 2021-03-17 | Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018140131A3 RU2018140131A3 (https=) | 2020-05-14 |
| RU2018140131A RU2018140131A (ru) | 2020-05-14 |
| RU2745912C2 true RU2745912C2 (ru) | 2021-04-02 |
Family
ID=58633040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018140131A RU2745912C2 (ru) | 2016-04-19 | 2017-04-19 | Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (https=) |
| EP (2) | EP4501406A3 (https=) |
| JP (3) | JP7387264B2 (https=) |
| KR (4) | KR102791288B1 (https=) |
| CN (2) | CN109069463B (https=) |
| AU (2) | AU2017252507B2 (https=) |
| BR (1) | BR112018071547A2 (https=) |
| CA (1) | CA3021155A1 (https=) |
| DK (1) | DK3445351T3 (https=) |
| ES (1) | ES2994242T3 (https=) |
| FI (1) | FI3445351T3 (https=) |
| HR (1) | HRP20241552T1 (https=) |
| HU (1) | HUE069219T2 (https=) |
| IL (3) | IL310508A (https=) |
| LT (1) | LT3445351T (https=) |
| MD (1) | MD3445351T2 (https=) |
| MX (2) | MX388461B (https=) |
| PL (1) | PL3445351T3 (https=) |
| PT (1) | PT3445351T (https=) |
| RS (1) | RS66142B1 (https=) |
| RU (1) | RU2745912C2 (https=) |
| SG (2) | SG10202106190RA (https=) |
| SI (1) | SI3445351T1 (https=) |
| SM (1) | SMT202400459T1 (https=) |
| WO (1) | WO2017182802A1 (https=) |
| ZA (1) | ZA201806849B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| WO2020178721A1 (en) * | 2019-03-02 | 2020-09-10 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
| US20250099355A1 (en) | 2023-07-18 | 2025-03-27 | Sytheon Ltd | Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008032222A2 (en) * | 2006-09-13 | 2008-03-20 | Pierre Fabre Medicament | Treatment of vertigo with acetyl-l-leucine |
| RU2012151575A (ru) * | 2010-06-03 | 2014-07-20 | Рауф РЕКИК | Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| CA2687107A1 (en) * | 2007-05-08 | 2008-11-13 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| US12458614B2 (en) * | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008032222A2 (en) * | 2006-09-13 | 2008-03-20 | Pierre Fabre Medicament | Treatment of vertigo with acetyl-l-leucine |
| RU2012151575A (ru) * | 2010-06-03 | 2014-07-20 | Рауф РЕКИК | Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин |
Non-Patent Citations (6)
| Title |
|---|
| KLAUS JAHN et al.: "Dizziness and Unstable Gait in Old Age - Etiology, Diagnosis and Treatment", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, 05.06.2015, vol.112, no.23, pp.387-393. * |
| MICHAEL STRUPP et al.: "Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, 09.07.2013, vol.260, no.10, pp.2556-2561. * |
| SHINICHI IWASAKI et al.: "Dizziness and Imbalance in the Elderly: Age-related Decline in the Vestibular System", AGING AND DISEASE, 02.02.2015, vol.6, no.1, pp.38-47. * |
| TATIANA BREMOVA et al.: "Acetyl-DL-leucine in Niemann-Pick type C: A case series", NEUROLOGY, 20.10.2015, vol.85, no.16, pp.1368-1375. * |
| TIGHILET BRAHIM et al.: "Comparative analysis of pharmacological treatments with N-acetyl-dl-leucine (Tanganil) and its two isomers (N-acetyl-L-leucine and N-acetyl-D-leucine) on vestibular compensation: Behavioral investigation in the cat", EUROPEAN JOURNAL OF PHARMACOLOGY, 19.11.2015, vol.769, pp. 42-349. * |
| АНТОНЕНКО Л.М. ВТОРОЙ КОНГРЕСС "МЕЖДУНАРОДНАЯ АКАДЕМИЯ ГОЛОВОКРУЖЕНИЯ", Неврологический журнал, 2015, т.20, с.51-53. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2745912C2 (ru) | Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| EP3802539C0 (en) | NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EA201891286A1 (ru) | АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HUE053239T2 (hu) | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| EP3641829A4 (en) | INTERFERON PRODRUG FOR TREATMENT OF CANCER | |
| EP3741861A4 (en) | SYNNOTCH RECEPTOR REGULATED EXPRESSION OF IL12 | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| HUE071155T2 (hu) | Biszkolin-tetratiomolibdát Wilson-kór kezelésére | |
| CA3015494C (en) | Novel compositions and therapeutic methods | |
| LT3463351T (lt) | Parkinsono ligos gydymas | |
| IL288894A (en) | Methods for the assessment and treatment of Alzheimer's disease and their applications | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP3735209A4 (en) | TREATMENT OF THE PROGRESSION OF MYOPOIA | |
| EP3897641C0 (en) | TREATMENT OF MOVEMENT DISORDERS | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| PT3603621T (pt) | Lipossomas para o tratamento de doenças oculares | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| EA202190359A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| EP3623369C0 (en) | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3672593C0 (en) | DRUGS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO VASOCONSTRICTION | |
| IL285160A (en) | Low dose pridopidine for parkinson’s disease and other diseases associated with parkinsonism | |
| WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease |